Literature DB >> 8492742

A cartilage explant system for studies on aggrecan structure, biosynthesis and catabolism in discrete zones of the mammalian growth plate.

A H Plaas1, J D Sandy.   

Abstract

The structure, biosynthesis and catabolism of aggrecan has been studied in the bovine fetal rib growth plate. Comparative analyses were made on six 1-mm transverse slices which represent the resting zone (slice 6), proliferative zone (slices 5 and 4), upper hypertrophic zone (slice 3), middle hypertrophic zone (slice 2) and lower hypertrophic zone (slice 1). Aggrecan was abundant and exhibited very high aggregability in all zones. The aggrecan monomer was similar in structure in the resting and proliferative zones but showed a marked increase in hydrodynamic size in the lower hypertrophic zone; this was apparently due to an increase in the size of substituent glycosaminoglycans and an increase in core protein size as indicated by peptide analysis for G3 domain abundance. Biosynthetic studies with [35S]-sulfate showed the rate of synthesis per cell to be highest in the upper hypertrophic zone, and the structure of the newly synthesised molecules to be similar to the resident population in all zones. During explant culture in basal medium both aggregating and non-aggregating forms of aggrecan were released slowly from all zones. Addition of 10 nM retinoic acid to explants stimulated the release of both these forms of aggrecan whereas higher concentrations of retinoic acid (100 nM and 1000 nM) preferentially stimulated the release of the degraded forms. In this regard hypertrophic cells were the most responsive and resting cells were the least responsive. Analysis of the degraded fragments by polyacrylamide gel electrophoresis and by N-terminal sequencing indicated that aggrecan catabolism in all zones of the growth plate is due to the action of aggrecanase, a novel cartilage proteinase which is also active in normal and osteoarthritic articular cartilages (Sandy et al., 1992). These observations are discussed in terms of the role of aggrecan in the extensive matrix remodelling which accompanies chondrocyte hypertrophy in the growth plate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492742     DOI: 10.1016/s0934-8832(11)80072-7

Source DB:  PubMed          Journal:  Matrix        ISSN: 0934-8832


  16 in total

1.  Effect of 1alpha,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo.

Authors:  D D Dean; B D Boyan; Z Schwart; O E Muniz; M R Carreno; S Maeda; D S Howell
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

2.  Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.

Authors:  M W Lark; E K Bayne; J Flanagan; C F Harper; L A Hoerrner; N I Hutchinson; I I Singer; S A Donatelli; J R Weidner; H R Williams; R A Mumford; L S Lohmander
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Adamts5 deletion blocks murine dermal repair through CD44-mediated aggrecan accumulation and modulation of transforming growth factor β1 (TGFβ1) signaling.

Authors:  Jennifer Velasco; Jun Li; Luisa DiPietro; Mary Ann Stepp; John D Sandy; Anna Plaas
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

4.  Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.

Authors:  C B Little; C R Flannery; C E Hughes; J S Mort; P J Roughley; C Dent; B Caterson
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

5.  "Aggrecanase" activity is implicated in tumour necrosis factor alpha mediated cartilage aggrecan breakdown but is not detected by an in vitro assay.

Authors:  D J Buttle; A Fowles; M Z Ilic; C J Handley
Journal:  Mol Pathol       Date:  1997-06

6.  Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development.

Authors:  Christopher B Little; Clare T Meeker; Rosalind M Hembry; Natalie A Sims; Kate E Lawlor; Sue B Golub; Karena Last; Amanda J Fosang
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

7.  Hyaluronate degradation as an alternative mechanism for proteoglycan release from cartilage during interleukin-1beta-stimulated catabolism.

Authors:  Robert Sztrolovics; Anneliese D Recklies; Peter J Roughley; John S Mort
Journal:  Biochem J       Date:  2002-03-01       Impact factor: 3.857

8.  Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent.

Authors:  A J Fosang; K Last; R A Maciewicz
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

9.  Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair.

Authors:  Christopher B Little; Clare T Meeker; Suzanne B Golub; Kate E Lawlor; Pamela J Farmer; Susan M Smith; Amanda J Fosang
Journal:  J Clin Invest       Date:  2007-05-17       Impact factor: 14.808

10.  Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine.

Authors:  J D Sandy; D Gamett; V Thompson; C Verscharen
Journal:  Biochem J       Date:  1998-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.